表紙
市場調查報告書

病毒載體製造的全球市場:成長,趨勢,預測(2019∼2024年)

Viral Vector Manufacturing Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 824090
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
病毒載體製造的全球市場:成長,趨勢,預測(2019∼2024年) Viral Vector Manufacturing Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年03月01日內容資訊: 英文 115 Pages
簡介

病毒載體製造市場,預計至2024年以19%的年複合成長率擴大。遺傳基因疾病,癌症,感染疾病的罹患率上升,臨床實驗的增加,基因治療開發的資金籌措,新的藥物輸送法的應用等帶動市場成長。

本報告提供全球病毒載體製造市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊彙整。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場趨勢

  • 市場概要
  • 推動市場的要素
    • 遺傳基因疾病,癌症,感染疾病的罹患率上升
    • 臨床實驗的增加和基因治療開發的資金籌措
    • 新的藥物輸送法的應用
  • 阻礙市場的要素
    • 基因治療成本高
    • 病毒載體製造能力的課題
  • 波特五力分析

第5章 市場區隔

  • 各類型
    • 腺病毒載體
    • 腺相關病毒載體
    • 慢病毒載體
    • 反轉錄病毒載體
    • 其他
  • 各疾病
    • 癌症
    • 遺傳基因疾病
    • 感染疾病
    • 其他
  • 各用途
    • 基因治療
    • 病毒學
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭趨勢

  • 企業簡介
    • Cobra Biologics
    • Finvector Oy
    • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    • Kaneka Corporation
    • Merck KGaA
    • Novasep Inc.
    • Oxford BioMedica Plc.
    • Sanofi SA
    • Spark Therapeutics Inc.
    • Thermo Fisher Scientific Inc.

第7章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64681

Market Overview

The viral vector manufacturing market is expected to register a CAGR of 19% over the forecast period. Certain factors that are driving the market include the rising prevalence of genetic disorders, cancer, and infectious diseases, the increasing number of clinical studies, and availability of funding for gene therapy development, and potential applications in novel drug delivery approaches.

Currently, several viral vector-based drugs have been approved. For instance, Gendicine™, the first gene therapy drug uses an oncolytic adenovirus vector, GlyberaRR (Alipogene tiparvovec) is a recombinant AAV product for lipoprotein lipase deficiency, and StrimvelisR which is a lentivirus vector for severe combined immunodeficiency (SCID) was approved in Europe. Furthermore, the second-generation oncolytic herpes simplex virus-1 expressing GM-CSF (Granulocyte-macrophage colony-stimulating factor) was recently approved for melanoma treatment in Europe and the United States, under the name T-vec (talimogene laherparepvec). Furthermore, there are significant government initiatives for the development of precision and personalized medicine in place, which are supplementing the R&D activities of academia and the industry. The government initiatives are driving the market's growth through direct funding, increasing awareness, and streamlining the regulatory environment via changes, such as fast track approval processes.

Hence, owing to the availability of funding, the market for viral vector manufacturing is expected to grow in the future.

Scope of the Report

As per the scope of this report, viral vectors represent one of the primary tools that can be used to deliver genetic material into cells. Viral vectors can be utilized in gene therapy, for the treatment of different diseases, such as heart defects, metabolic diseases, cancers, and neurodegenerative disorders. Viral vectors that are based on adenoviruses, adeno-associated viruses, lentiviruses, retroviruses, herpes simplex viruses, and baculovirus, among others, are being routinely used in life science research, and are finding their applications in vaccinology and novel drug delivery approaches.

The report gives a detailed analysis of the types of viral vectors, the diseases it deals with, and its applications along with the geographical considerations.

Key Market Trends

The Cancer Sub-segment is Expected to Grow Faster in the Disease Segment

In the field of oncology, viral vector-based gene therapy has demonstrated steady progress. A multitude of viral vectors has been engineered for both therapeutic and preventive applications, in cancers. A critical development in viral vector-based cancer therapy has been the application of engineered and naturally occurring oncolytic viral vectors. These vectors are programmed to specifically replicate inside the cancer cells and induce toxic effects, which ultimately results in apoptosis. The attractive features of viral vectors relate to their capability to provide high levels of transgene expression, in a broad range of host cells.

The high demand for effective therapeutics for the management of cancers, the presence of fast track approval process, and the prospects of novel drugs to turn into blockbuster products are primary reasons responsible for the significant R&D investments in the field of viral vector-based cancer therapeutics, which, in turn, is driving the market's growth.

North America Dominates the Market and is Expected to Follow the Same Trend in the Future As Well

North America currently dominates the market for viral vector manufacturing and is expected to continue its stronghold for a few more years. The United States holds the largest market share in the North American region owing to factors, such as the high adoption rate of new therapies and high awareness of the general population. The increasing prevalence of genetic and chronic disorders, such as cancer, an aging population, growing demand for targeted and personalized medicine, and favorable government initiatives are the factors responsible for the significant market size in the United States.

Competitive Landscape

The viral vector manufacturing market is moderately competitive and has several key players, such as Sanofi SA, Merck KgaA, Fujifilm Diosynth Biotechnologies, Thermofisher Scientific, and Oxford BioMedica. Owing to the growing demand for novel therapeutics to deal with life-threatening diseases, such as cancer, various smaller companies are also entering the market and holding a significant market share.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
    • 4.2.2 Increasing Number of Clinical Studies And Availability of Funding For Gene Therapy Development
    • 4.2.3 Potential Applications in Novel Drug Delivery Approaches
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Gene Therapies
    • 4.3.2 Challenges in Viral Vector-manufacturing Capacity
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Adenoviral Vectors
    • 5.1.2 Adeno-associated Viral Vectors
    • 5.1.3 Lentiviral Vectors
    • 5.1.4 Retroviral Vectors
    • 5.1.5 Other Types
  • 5.2 By Disease
    • 5.2.1 Cancer
    • 5.2.2 Genetic Disorders
    • 5.2.3 Infectious Diseases
    • 5.2.4 Other Diseases
  • 5.3 By Application
    • 5.3.1 Gene therapy
    • 5.3.2 Vaccinology
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Cobra Biologics
    • 6.1.2 Finvector Oy
    • 6.1.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
    • 6.1.4 Kaneka Corporation (Eurogentec)
    • 6.1.5 Merck KGaA
    • 6.1.6 Novasep Inc.
    • 6.1.7 Oxford BioMedica Plc.
    • 6.1.8 Sanofi SA
    • 6.1.9 Spark Therapeutics Inc.
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS